Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Y Oh

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|May 8, 2020
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignanciesJason Cham, Li Zhang, Serena Kwek, et al.
Cancer Research|December 30, 2016
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell RepertoireDavid Y Oh, Jason Cham, Li Zhang, et al.
Cancer Immunology Research|September 24, 2020
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-TLi Zhang, Harini Kandadi, Hai Yang, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patientsElliot Naidus, Jerome Bouquet, David Y Oh, et al.
Briefings in Bioinformatics|July 24, 2025
PepTCR-Net: prediction of multi-class antigen peptides by T-cell receptor sequences with deep learningPhi Le, Leah Ung, Hai Yang, et al.
Anticancer Research|June 4, 2021
Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to ImmunotherapyBridget P Keenan, Katherine VAN Loon, Anuradha D Khilnani, et al.
Cancer Cell|December 15, 2021
Toward a better understanding of T cells in cancerDavid Y Oh, Lawrence Fong, Evan W Newell, et al.
ACS Central Science|November 3, 2021
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PETNing Zhao, Conner Bardine, André Luiz Lourenço, et al.
Nature Medicine|July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim resultsRaffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
Molecular Imaging and Biology|August 20, 2020
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET RadiotracersJunnian Wei, Yung-Hua Wang, Chia Yin Lee, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|May 8, 2020
Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignanciesJason Cham, Li Zhang, Serena Kwek, et al.
Cancer Research|December 30, 2016
Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell RepertoireDavid Y Oh, Jason Cham, Li Zhang, et al.
Cancer Immunology Research|September 24, 2020
Long-term Sculpting of the B-cell Repertoire following Cancer Immunotherapy in Patients Treated with Sipuleucel-TLi Zhang, Harini Kandadi, Hai Yang, et al.
Cancer Immunology, Immunotherapy : CII|January 9, 2021
Early changes in the circulating T cells are associated with clinical outcomes after PD-L1 blockade by durvalumab in advanced NSCLC patientsElliot Naidus, Jerome Bouquet, David Y Oh, et al.
Briefings in Bioinformatics|July 24, 2025
PepTCR-Net: prediction of multi-class antigen peptides by T-cell receptor sequences with deep learningPhi Le, Leah Ung, Hai Yang, et al.
Anticancer Research|June 4, 2021
Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to ImmunotherapyBridget P Keenan, Katherine VAN Loon, Anuradha D Khilnani, et al.
Cancer Cell|December 15, 2021
Toward a better understanding of T cells in cancerDavid Y Oh, Lawrence Fong, Evan W Newell, et al.
ACS Central Science|November 3, 2021
In Vivo Measurement of Granzyme Proteolysis from Activated Immune Cells with PETNing Zhao, Conner Bardine, André Luiz Lourenço, et al.
Nature Medicine|July 27, 2023
Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim resultsRaffit Hassan, Marcus Butler, Roisin E O'Cearbhaill, et al.
Molecular Imaging and Biology|August 20, 2020
An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET RadiotracersJunnian Wei, Yung-Hua Wang, Chia Yin Lee, et al.
Pageof 4